Compound News and Research

RSS

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals.

2 Oct 2013

libragen contributes to success of PolyModE

libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.

2 Oct 2013

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

2 Oct 2013

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Resveratrol, a naturally occurring polyphenol compound produced by the skin of red grapes and peanuts, and found in red wine, has been touted as a beneficial supplement due to its anti-inflammatory and antioxidant properties.

1 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

Researchers develop C6 compound that prevents abnormalities linked with priapism in mice

It's not the little blue pill famous for helping men get big results, but for those who need it, the outcome might be even more significant. A new research report published online in The FASEB Journal, offers hope to men who experience priapism. This condition, which is often seen in men with sickle cell disease, causes erections lasting so long that they cause permanent damage to the penis.

1 Oct 2013

Battle over health law brings gov't to brink of shutdown

A stopgap bill to fund the government when the fiscal year ends Oct. 1 continues to be caught up in Republican efforts to defund, delay or derail the health law. Federal agencies have contingency plans in place.

1 Oct 2013

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

...

30 Sep 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

...

27 Sep 2013

Designing safer titanium dioxide for human use

Using a particular type of titanium dioxide - a common ingredient in cosmetics, food products, toothpaste and sunscreen - could reduce the potential health risks associated with the widely used compound. The report on the substance, produced by the millions of tons every year for the global market, appears in the ACS journal Chemical Research in Toxicology.

26 Sep 2013

FM market for healthcare in Australia expected to grow at annual rate of 3.1%, finds new analysis

In 2012, the public healthcare sector in Australia was more than twice the size of the private healthcare sector in terms of hospital beds and total hospital expenditure. While private healthcare and other small to medium medical facilities do provide facilities management opportunities, it is mostly to small and medium FM companies. The larger and well-established FM providers will mostly come into play with the successful implementation of public private partnerships model in the healthcare sector.

25 Sep 2013

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.

23 Sep 2013

Cellectricon awards Cellaxess ACE project grant to support research in cell biology

Cellectricon, a leading provider of advanced cell-based screening technologies and services, has announced the two winners of its Cellaxess ACE project grant, supporting cutting-edge research in cell biology.

From Cellectricon 21 Sep 2013

Dog food preservative may prevent nerve damage in patients taking chemotherapy

Working with cells in test tubes and in mice, researchers at Johns Hopkins have discovered that a chemical commonly used as a dog food preservative may prevent the kind of painful nerve damage found in the hands and feet of four out of five cancer patients taking the chemotherapy drug Taxol.

20 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Compound News and Research

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

libragen contributes to success of PolyModE

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

Researchers develop C6 compound that prevents abnormalities linked with priapism in mice

Battle over health law brings gov't to brink of shutdown

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

Designing safer titanium dioxide for human use

FM market for healthcare in Australia expected to grow at annual rate of 3.1%, finds new analysis

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Cellectricon awards Cellaxess ACE project grant to support research in cell biology

Dog food preservative may prevent nerve damage in patients taking chemotherapy

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News